Cancer recognition of artificial intelligence

doi:10.35713/aic.v2.i1.1

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 2, Issue 1

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7764)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-1) series.

Item

Count

PDF

406

WORD

262

HTML

3039

Figures (1-1)

367

Tables (1-1)

352

Sum=4426

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

350

Download

1120

Sum=1470

Publishing Process of This Article

Item

Count

Browse

547

Download

1321

Sum=1868

Feb 28, 2021 (publication date) through Dec 30, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

Artificial Intelligence in Cancer

ISSN

2644-3228

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

Artif Intell Cancer. Feb 28, 2021; 2(1): 1-6
Published online Feb 28, 2021. doi: 10.35713/aic.v2.i1.1

Cancer recognition of artificial intelligence

Shihori Tanabe

Shihori Tanabe, Division of Risk Assessment, Center for Biological Safety and Research, National Institute of Health Sciences, Kawasaki 210-9501, Kanagawa, Japan

Author contributions: Tanabe S contributed to the writing and editing of the manuscript.

Supported by Japan Agency for Medical Research and Development (AMED), No. JP20ak0101093.

Conflict-of-interest statement: The author has nothing to disclose.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Shihori Tanabe, PhD, Senior Researcher, Division of Risk Assessment, Center for Biological Safety and Research, National Institute of Health Sciences, 3-25-26, Tonomachi, Kawasaki-ku, Kawasaki 210-9501, Kanagawa, Japan. stanabe@nihs.go.jp

Received: February 12, 2021
Peer-review started: February 12, 2021
First decision: February 19, 2021
Revised: February 28, 2021
Accepted: February 28, 2021
Article in press: February 28, 2021
Published online: February 28, 2021
Processing time: 25 Days and 3.3 Hours

Core Tip

Core Tip: Recently, rapidly growing advances in deep learning have enabled cancer recognition by artificial intelligence (AI). Differences between human insights and AI attention may exist, and the interpretation of the modeling would lead to the further progression of AI-oriented therapeutics. The massive ability of AI is useful for cancer recognition.